Skip to main content
Top
Published in: Diabetologia 12/2010

01-12-2010 | Short Communication

Maturity-onset diabetes of the young (MODY): how many cases are we missing?

Authors: B. M. Shields, S. Hicks, M. H. Shepherd, K. Colclough, A. T. Hattersley, S. Ellard

Published in: Diabetologia | Issue 12/2010

Login to get access

Abstract

Aims/hypothesis

Maturity-onset diabetes of the young is frequently misdiagnosed as type 1 or type 2 diabetes. A correct diagnosis of MODY is important for determining treatment, but can only be confirmed by molecular genetic testing. We aimed to compare the regional distribution of confirmed MODY cases in the UK and to estimate the minimum prevalence.

Methods

UK referrals for genetic testing in 2,072 probands and 1,280 relatives between 1996 and 2009 were examined by region, country and test result. Referral rate and prevalence were calculated using UK Census 2001 figures.

Results

MODY was confirmed in 1,177 (35%) patients, with HNF1A (52%) and GCK mutations (32%) being most frequent in probands confirmed with MODY. There was considerable regional variation in proband referral rates (from <20 per million in Wales and Northern Ireland to >50 per million for South West England and Scotland) and patients diagnosed with MODY (5.3 per million in Northern Ireland, 48.9 per million in South West England). Referral rates and confirmed cases were highly correlated (r = 0.96, p < 0.0001). The minimum prevalence of MODY was estimated to be 108 cases per million.

Conclusions/interpretation

Assuming this minimal prevalence throughout the UK then >80% of MODY is not diagnosed by molecular testing. The marked regional variation in the prevalence of confirmed MODY directly results from differences in referral rates. This could reflect variation in awareness of MODY or unequal access to genetic testing. Increased referral for diagnostic testing is required if the majority of MODY patients are to have the genetic diagnosis necessary for optimal treatment.
Appendix
Available only for authorised users
Literature
1.
go back to reference Tattersall RB (1974) Mild familial diabetes with dominant inheritance. Q J Med 43:339–357PubMed Tattersall RB (1974) Mild familial diabetes with dominant inheritance. Q J Med 43:339–357PubMed
2.
go back to reference Shepherd M, Shields B, Ellard S, Rubio-Cabezas O, Hattersley AT (2009) A genetic diagnosis of HNF1A diabetes alters treatment and improves glycaemic control in the majority of insulin-treated patients. Diabet Med 26:437–441CrossRefPubMed Shepherd M, Shields B, Ellard S, Rubio-Cabezas O, Hattersley AT (2009) A genetic diagnosis of HNF1A diabetes alters treatment and improves glycaemic control in the majority of insulin-treated patients. Diabet Med 26:437–441CrossRefPubMed
3.
go back to reference Estalella I, Rica I, Perez de Nanclares G et al (2007) Mutations in GCK and HNF-1alpha explain the majority of cases with clinical diagnosis of MODY in Spain. Clin Endocrinol (Oxf) 67:538–546 Estalella I, Rica I, Perez de Nanclares G et al (2007) Mutations in GCK and HNF-1alpha explain the majority of cases with clinical diagnosis of MODY in Spain. Clin Endocrinol (Oxf) 67:538–546
4.
go back to reference Chevre JC, Hani EH, Boutin P et al (1998) Mutation screening in 18 Caucasian families suggest the existence of other MODY genes. Diabetologia 41:1017–1023CrossRefPubMed Chevre JC, Hani EH, Boutin P et al (1998) Mutation screening in 18 Caucasian families suggest the existence of other MODY genes. Diabetologia 41:1017–1023CrossRefPubMed
5.
go back to reference Murphy R, Ellard S, Hattersley AT (2008) Clinical implications of a molecular genetic classification of monogenic beta-cell diabetes. Nat Clin Pract Endocrinol Metab 4:200–213CrossRefPubMed Murphy R, Ellard S, Hattersley AT (2008) Clinical implications of a molecular genetic classification of monogenic beta-cell diabetes. Nat Clin Pract Endocrinol Metab 4:200–213CrossRefPubMed
6.
go back to reference Panzram G, Adolph W (1981) Heterogeneity of maturity onset diabetes at young age (MODY). Lancet 2:986CrossRefPubMed Panzram G, Adolph W (1981) Heterogeneity of maturity onset diabetes at young age (MODY). Lancet 2:986CrossRefPubMed
7.
go back to reference Ledermann HM (1995) Maturity-onset diabetes of the young (MODY) at least ten times more common in Europe than previously assumed? Diabetologia 38:1482CrossRefPubMed Ledermann HM (1995) Maturity-onset diabetes of the young (MODY) at least ten times more common in Europe than previously assumed? Diabetologia 38:1482CrossRefPubMed
8.
go back to reference Schober E, Rami B, Grabert M et al (2009) Phenotypical aspects of maturity-onset diabetes of the young (MODY diabetes) in comparison with type 2 diabetes mellitus (T2DM) in children and adolescents: experience from a large multicentre database. Diabet Med 26:466–473CrossRefPubMed Schober E, Rami B, Grabert M et al (2009) Phenotypical aspects of maturity-onset diabetes of the young (MODY diabetes) in comparison with type 2 diabetes mellitus (T2DM) in children and adolescents: experience from a large multicentre database. Diabet Med 26:466–473CrossRefPubMed
9.
go back to reference Eide SA, Raeder H, Johansson S et al (2008) Prevalence of HNF1A (MODY3) mutations in a Norwegian population (the HUNT2 Study). Diabet Med 25:775–781CrossRefPubMed Eide SA, Raeder H, Johansson S et al (2008) Prevalence of HNF1A (MODY3) mutations in a Norwegian population (the HUNT2 Study). Diabet Med 25:775–781CrossRefPubMed
10.
go back to reference Ellard S, Bellanne-Chantelot C, Hattersley AT (2008) Best practice guidelines for the molecular genetic diagnosis of maturity-onset diabetes of the young. Diabetologia 51:546–553CrossRefPubMed Ellard S, Bellanne-Chantelot C, Hattersley AT (2008) Best practice guidelines for the molecular genetic diagnosis of maturity-onset diabetes of the young. Diabetologia 51:546–553CrossRefPubMed
11.
go back to reference Porter JR, Rangasami JJ, Ellard S et al (2006) Asian MODY: are we missing an important diagnosis? Diabet Med 23:1257–1260CrossRefPubMed Porter JR, Rangasami JJ, Ellard S et al (2006) Asian MODY: are we missing an important diagnosis? Diabet Med 23:1257–1260CrossRefPubMed
12.
go back to reference Shepherd M, Hattersley AT, Ellard S (2005) Integration of the MODY link nurse project: 20 month evaluation. J Diabetes Nurs 9:47–52 Shepherd M, Hattersley AT, Ellard S (2005) Integration of the MODY link nurse project: 20 month evaluation. J Diabetes Nurs 9:47–52
Metadata
Title
Maturity-onset diabetes of the young (MODY): how many cases are we missing?
Authors
B. M. Shields
S. Hicks
M. H. Shepherd
K. Colclough
A. T. Hattersley
S. Ellard
Publication date
01-12-2010
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 12/2010
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-010-1799-4

Other articles of this Issue 12/2010

Diabetologia 12/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.